Martine Rothblatt Sells 9,500 Shares of United Therapeutics (NASDAQ:UTHR) Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the firm’s stock in a transaction on Monday, April 20th. The shares were sold at an average price of $577.83, for a total transaction of $5,489,385.00. Following the transaction, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $23,409,626.79. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

United Therapeutics Stock Performance

UTHR stock opened at $574.29 on Thursday. The company has a fifty day moving average price of $532.71 and a 200-day moving average price of $492.68. The company has a market capitalization of $25.17 billion, a P/E ratio of 20.58, a PEG ratio of 1.63 and a beta of 0.75. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $607.89.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 25th. The biotechnology company reported $7.70 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.78 by $0.92. The firm had revenue of $790.20 million during the quarter, compared to the consensus estimate of $814.80 million. United Therapeutics had a net margin of 41.94% and a return on equity of 19.30%. The company’s revenue for the quarter was up 7.4% on a year-over-year basis. During the same quarter last year, the firm earned $6.19 earnings per share. As a group, sell-side analysts forecast that United Therapeutics Corporation will post 27.97 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on UTHR shares. Wells Fargo & Company lifted their target price on shares of United Therapeutics from $486.00 to $575.00 and gave the stock an “equal weight” rating in a research note on Tuesday, March 31st. Bank of America lifted their target price on shares of United Therapeutics from $569.00 to $626.00 and gave the stock a “neutral” rating in a research note on Tuesday, March 31st. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research note on Monday, December 29th. TD Cowen lifted their target price on shares of United Therapeutics from $575.00 to $660.00 and gave the stock a “buy” rating in a research note on Monday, March 30th. Finally, Cantor Fitzgerald lifted their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Ten investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $601.50.

Institutional Investors Weigh In On United Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of UTHR. Torren Management LLC bought a new stake in United Therapeutics in the fourth quarter valued at $26,000. Activest Wealth Management increased its stake in United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 56 shares in the last quarter. WealthCollab LLC increased its stake in United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Rakuten Securities Inc. increased its stake in United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after purchasing an additional 46 shares in the last quarter. Finally, Entrust Financial LLC bought a new stake in United Therapeutics in the fourth quarter valued at $31,000. 94.08% of the stock is owned by institutional investors.

United Therapeutics News Roundup

Here are the key news stories impacting United Therapeutics this week:

• Positive Sentiment: Company to present encouraging clinical and program data (ARTISAN/PHINDER interim analyses) at ISHLT — results highlight earlier detection/management of pulmonary hypertension, right‑ventricular benefits with high‑dose treprostinil, and progress on lung donor expansion/xenotransplantation, which support longer‑term pipeline value and revenue upside. Read More.
• Positive Sentiment: Analysts remain constructive with multiple price‑target raises and a consensus “Moderate Buy” (~$601.50 average), which provides valuation support that can limit downside if upcoming clinical/earnings news is positive.
• Positive Sentiment: Longer‑term bull thesis highlighted around manufactured organs/xenotransplantation — bullish pieces argue these programs (if successful and approved) could materially re‑rate the company over the next several years. Read More.
• Neutral Sentiment: United Therapeutics will report Q1 results before market open on May 6; Zacks notes the company has setup attributes that could support an earnings beat — this calendar catalyst can drive short‑term volatility in either direction. Read More. Read More.
• Neutral Sentiment: Some institutional reweighting — Asset Management One modestly trimmed its stake (≈5.1%), a small adjustment rather than a large outflow that’s unlikely to move the stock materially on its own. Read More.
• Neutral Sentiment: Unusually large options activity has been reported, indicating elevated short‑term trading and hedging interest — this can amplify intraday moves but is directionally ambiguous. Read More.
• Negative Sentiment: CEO Martine Rothblatt sold 9,500 shares (~$5.5M) in mid‑April, reducing her stake by ~19% — a high‑profile insider sale that often raises investor concerns about near‑term sentiment. Read More.
• Negative Sentiment: CFO James Edgemond sold 10,000 shares (~$5.78M) around the same dates — multiple senior executive sales in quick succession increase perceived selling pressure. Read More.
• Negative Sentiment: Additional director insider sales have been reported, adding to the pattern of recent insider liquidations that can weigh on near‑term investor sentiment. Read More.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.